Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Featured
Page 85
Featured
Featured posts
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
BridgeBio’s BEYONTTRA approved by European Commission to treat ATTR-CM
UK unveils funding for AI companies to transform cancer care and spark new drug breakthroughs
Aitia and UCB form strategic drug discovery collaboration in Huntington’s disease
17th March 2023
Revolutionary new bone cancer drug could save children’s lives
15th March 2023
Sanofi to acquire Provention Bio
14th March 2023
Takeda’s dengue vaccine approved in Brazil
14th March 2023
Pfizer invests $43 billion in Seagen acquisition
14th March 2023
Acadia Pharmaceuticals receives U.S. FDA approval for Rett syndrome treatment
13th March 2023
Sandoz signs Memorandum of Understanding to build new biologics production plant...
13th March 2023
Pfizer’s migraine nasal spray receives FDA approval
13th March 2023
ModeX Therapeutics enters into exclusive worldwide license and collaboration agreement with...
10th March 2023
Cancer Research UK signs multi-project collaboration with UCB to develop antibody...
9th March 2023
1
...
84
85
86
...
146
Page 85 of 146
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...